Abstract:Objective To detect the expression of peripheral blood free prostate specific antigen (fSPA),total prostate specific antigen (tSPA),prostate specific antigen density (PSAD) and prostate cancer gene 3 (PCA3) in prostate disease,and the significance of combined detection of fSPA,tSPA and PCA3.Methods 67 patients with prostate cancer,75 patients with prostatic hyperplasia and 70 healthy male were selected as the research objects from Dec.2014 to Jul.2016.The serum level of fSPA and tSPA was detected by chemiluminescence immune staining method.The prostate volume was tested by ultrasonic sound and PSAD value was calculated.The total RNA was extracted by Trizol,and the serum PCA3 mRNA expression was detected by RT-PCR.The specificity and sensitivity of combined detection of fSPA,tSPA and PCA3 were analyzed.Results The serum levels of fSPA,tSPA,PSAD and PCA3 in prostate cancer were significantly higher than those in patients with prostatic hyperplasia and healthy male,and they were higher in patients with hyperplasia of prostate than in healthy male,and the differences had statistical significance (P＜0.01).The serum levels of fSPA,tSPA,PSAD and PCA3 were higher in patients with Gleason score ≥7 points and in T3-T4 stage than in patients with Gleason score ＜7 and in T1-T2 stage,and the difference had statistical significance (P＜0.01).The serum levels of fSPA,tSPA,PSAD and PCA3 were positively correlated with Gleason score and TMN pathological stage,and the difference had statistical significance (P＜0.01).The AUC value of fSPA,tSPA,PSAD and PCA3 in diagnosis of prostate cancer was 0.53,0.57,0.63 and 0.75,and the AUC value of combined detection was 0.92.The combined detection efficiency was higher than the single index.The specificity of fSPA,tSPA,PSAD and PCA3 was 67.16％,68.66％,73.13％ and 85.07％,and the sensitivity was 71.64％,70.15％,74.63％ and 82.09％ respectively.The specificity of combined detection was 97.01％,the sensitivity was 92.54％,and the difference had statistical significance (P＜0.01).Conclusion The serum level of fSPA,tSPA,PSAD and PCA3 is increased in prostate disease,and is negatively correlated with Gleason score and TMN pathological stage.The combined detection of fSPA,tSPA,PSAD and PCA3 can improve the sensitivity and specificity of prostate disease diagnosis,and is of high clinical value.

Structural alterations and significance of sugar chains of PSA in urine and blood from BPH and Pca patients

Effect of Hypertension on Bacteria Composition of Prostate Biopsy in Patients with Benign Prostatic Hyperplasia and Prostate Cancer in PSA Grey-Zone.

[Detection of Urine DD3/PSA Mrna Ratio by Duplex TaqMan RT-PCR Assay and Evolution of Its Primary Application].

Applied Research of Prostate Specific Antigen Combined with Prostate Cancer Gene 3 in Diagnosis of Prostate Disease

Semen As a Rich Source of Diagnostic Biomarkers for Prostate Cancer: Latest Evidence and Implications

Clinical Significance of Urine Prostatic Exosomal Protein in the Diagnosis of Prostate Cancer.

Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach

Advances in Biomarkers for the Early Diagnosis of Prostate Cancer.

Percent Free Prostate-Specific Antigen for Prostate Cancer Diagnosis in Chinese Men with a PSA of 4.0–10.0 Ng/ml: Results from the Chinese Prostate Cancer Consortium

Increased α2,3‐sialyl N‐glycosylated prostate‐specific membrane antigen (PSMA) in post‐DRE urine is associated with high grade group prostate cancer

SERS-based biosensor for detection of f-PSA%: Implications for the diagnosis of prostate cancer

Changes of the Density of Prostate Specific Antigen in Benign of Prostate Hyperplasia and Prostatic Cancer

Changes and clinilcal significances of serum total prostate-specific antigen,free prostate-specific antigen and free/total prostate-specific antigen in patients with benign and malignant prostatic diseases

Unveiling the potential of SLURP1 protein as a biomarker for prostate cancer screening

PSAD and Free-to-Total PSA Ratio in Patients with Prostate Cancer or Benign Prostatic Hyperplasia

The Utility of Complexed Prostate Specific Antigen Density(cPSAD) for Early Detection Proatate Cancer in Han Population with Different Serum PSA Levels

The role of the ratio of serum PSA and urine PSA in diagnosing prostate carcinoma within the serum PSA "gray" zone

Elevated Serum Sialic Acid Levels Predict Prostate Cancer As Well As Bone Metastases

The clinical significance of percent free PSA in differentiating prostate cancer and benign prostate hyperplasia

A Comparative Study of PSA,PSAD and PSAT in the Diagnosis of Prostate Cancer

Clinical Significance of Determination of Serum IGF-1, IGFBP-3 Levels in Patients with Prostate Cancer